Skip to content
Subscriber Only

J&J-Pfizer Drug Seen as Long Shot Against Alzheimer’s

When 70-year-old Bill Price signed on in 2006 to become one of the early testers of the Alzheimer’s drug bapineuzumab, he held high hopes the injections would stop the disease that was starting to claim his memory.

Intended to eliminate plaques in the brain that are a hallmark of the illness, bapineuzumab is a project of Johnson & Johnson, Pfizer Inc. and Elan Corp. The three companies are racing Eli Lilly & Co. to market the first broadly available drug designed to target a cause of Alzheimer’s, rather than just its symptoms.